GVHD treatment given Orphan status


A joint release from both Accentia Biopharmaceuticals and Biovest international announced that Accentia's proprietary treatment regimen for graft-vs-host-disease (GVHD) following a bone marrow transplant has been granted Orphan Drug status by the Food & Drug Administration.

The treatment is a system of care that uses high dose administration of a drug familiar to many blood cancer patients, Cytoxan (cyclophosphamide).

GVHD--in which the donor marrow begins attacking the host-- is perhaps the most serious risk following an allogeneic bone marrow transplant, and is often fatal.

LymphomaInfo Social